Skip to content

Alumis Inc. ALMS Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.85B+8.4%
Amgen logo
AmgenAMGN
$2.37B+7.0%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$16.45M+134%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$3.11M+22.4%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$8.45M+25.0%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.17B+739%
Enterprise value$3.14B+1,238%
P/S377.1×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s other non-current liabilities?
Alumis Inc. (ALMS) reported other non-current liabilities of $207K in Q1 2026.
What does other non-current liabilities mean?
Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.